Efficacy of

Hadiseh Kavandi, Mehrzad Hajialilo, Alireza Khabbazi

Open access · greenAbstract read

In one paragraph

Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.4field-weighted citation impact, top 36% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hadiseh KavandiConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mehrzad HajialiloConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Alireza KhabbaziConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Tabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMATERIALS AND

methodsIn this double-blind randomized controlled study, 130 patients with BD were screened and 71 patients with BD were randomly allocated to the treatment (n=37) and control (n=34) groups. Finally, 32 and 30 patients in the treatment and control groups, respectively, completed the study. The study protocol was registered in the Iranian Registry of Clinical Trials (IRCT) with registration No. IRCT201511086975N5. Treatment and control groups received soft gels containing 1000 mg NS oil or 1000 mg placebo per day for 12 months, respectively. Disease activity using the Iranian Behcet's disease dynamic activity measure (IBDDAM), total inflammatory activity index (TIAI) and Behcet's disease current activity form (BDCAF) were evaluated in all patients before initiation of the trial and every 2 months, for 12 months.

resultsDisease activity decreased in the study groups; difference between the two groups was not significant. No serious adverse events were seen in the treatment and control groups.

conclusionNS oil at the dose of 1000 mg/day is not effective in controlling BD activity.

Indexed as

Behcet's diseaseBehcet’s disease current activity form (BDCAF)Iranian Behcet’s disease dynamic activity measure (IBDDAM)Nigella sativa

Identifiers

PMID30456197

PMCPMC6235660

OpenAlexW2810819619

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.